Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Acta Biomater ; 167: 387-400, 2023 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-37276955

RESUMEN

The tumor microenvironment of pancreatic ductal adenocarcinoma (PDAC) is the main block for the penetration of chemotherapy. In the tumor microenvironment, a dense matrix composed of fibrin is formed on the exterior, while the interior is featured by high reduction, hypoxia and low pH. How to match the special microenvironment to on-demand drug release is the key to improve chemotherapeutic efficacy. Herein, a microenvironment-responsive micellar system is developed to deepen tumoral penetration. Briefly, the conjugation of a fibrin-targeting peptide to PEG-poly amino acid has been utilized to achieve accumulation of micelles in the tumor stroma. By modification of micelles with hypoxia-reducible nitroimidazole which becomes protonated under acidic conditions, their surface charge is more positive, facilitating deeper penetration into tumors. Paclitaxel was loaded onto the micelles via a disulfide bond to enable glutathione (GSH)-responsive release. Therefore, the immunosuppressive microenvironment is relived through the alleviation of hypoxia and depletion of GSH. Hopefully, this work could establish paradigms by designing sophisticated drug-delivery systems to tactfully employ and retroact the tamed tumoral microenvironment to improve the therapeutic efficacy based on understanding the multiple hallmarks and learning the mutual regulation. STATEMENT OF SIGNIFICANCE: Tumor microenvironment(TME) is an unique pathological feature of pancreatic cancer and an inherent barrier to chemotherapy. Numerous studies regard TME as the targets for drug delivery. In this work, we propose a hypoxia-responsive nanomicellar drug delivery system that aiming hypoxia TME of pancreatic cancer. The nanodrug delivery system could respond to the hypoxic microenvironment and enhance the penetration of the inner tumor at the same time preserving the outer tumor stroma, thus achieving targeted treatment of PDAC by preserving the integrity of the outer stroma. Simultaneously, the responsive group can reverse the degree of hypoxia in TME by disrupting the redox balance in the tumor region, thus achieving precise treatment of PDAC by matching the pathological characteristics of TME. We believe our article would provide new design ideas for the future treatments for pancreatic cancer.


Asunto(s)
Carcinoma Ductal Pancreático , Neoplasias Pancreáticas , Humanos , Micelas , Microambiente Tumoral , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/patología , Carcinoma Ductal Pancreático/patología , Hipoxia , Glutatión , Terapia de Inmunosupresión , Línea Celular Tumoral , Neoplasias Pancreáticas
2.
ACS Nano ; 17(8): 7847-7864, 2023 04 25.
Artículo en Inglés | MEDLINE | ID: mdl-37039779

RESUMEN

Medicinal treatment against epilepsy is faced with intractable problems, especially epileptogenesis that cannot be blocked by clinical antiepileptic drugs (AEDs) during the latency of epilepsy. Abnormal circuits of neurons interact with the inflammatory microenvironment of glial cells in epileptic foci, resulting in recurrent seizures and refractory epilepsy. Herein, we have selected phenytoin (PHT) as a model drug to derive a ROS-responsive and consuming prodrug, which is combined with an electro-responsive group (sulfonate sodium, SS) and an epileptic focus-recognizing group (α-methyl-l-tryptophan, AMT) to form hydrogel nanoparticles (i.e., a nanogel). The nanogel will target epileptic foci, release PHT in response to a high concentration of reactive oxygen species (ROS) in the microenvironment, and inhibit overexcited circuits. Meanwhile, with the clearance of ROS, the nanogel can also reduce oxidative stress and alleviate microenvironment inflammation. Thus, a synergistic regulation of epileptic lesions will be achieved. Our nanogel is expected to provide a more comprehensive strategy for antiepileptic treatment.


Asunto(s)
Epilepsia , Humanos , Especies Reactivas de Oxígeno/uso terapéutico , Nanogeles , Epilepsia/tratamiento farmacológico , Anticonvulsivantes/farmacología , Anticonvulsivantes/uso terapéutico , Fenitoína
3.
Bioorg Chem ; 128: 106112, 2022 11.
Artículo en Inglés | MEDLINE | ID: mdl-36070628

RESUMEN

Herein, two series of HDAC/tubulin dual inhibitors via introducing the key pharmacophore of HDAC inhibitor into the skeletons of 2,6-diarylpyridine and 2'-arylchalcone were synthesized. Among them, 2,6-diarylpyridine-based hydroxamic acid 10a exhibited good inhibitory activity against HDAC8 (IC50 = 117 nM) with 50-fold and 42-fold high selectivity relative to HDAC1 and HDAC6, respectively. Meanwhile, 10a disrupted tubulin polymerization effectively and exhibited potent antiproliferative activity against BE-(2)-C cell line, with IC50 value of 17 nM. Mechanism studies revealed that 10a blocked cell cycle, induced cellular apoptosis and suppressed colony formation. Moreover, 10a possessed good physicochemical properties and metabolic stability. Importantly, 10a exhibited better antitumor effects in human neuroblastoma xenograft mice model than those of clinical HDAC inhibitor and tubulin inhibitor, whether used alone or in combination. These results highlighted the advantages of the HDAC8/tubulin dual inhibitor 10a as an outstanding antitumor agent.


Asunto(s)
Antineoplásicos , Neuroblastoma , Animales , Antineoplásicos/química , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Línea Celular Tumoral , Proliferación Celular , Inhibidores de Histona Desacetilasas/química , Inhibidores de Histona Desacetilasas/farmacología , Inhibidores de Histona Desacetilasas/uso terapéutico , Histona Desacetilasas/metabolismo , Humanos , Ácidos Hidroxámicos/química , Ácidos Hidroxámicos/farmacología , Ácidos Hidroxámicos/uso terapéutico , Ratones , Neuroblastoma/tratamiento farmacológico , Proteínas Represoras/metabolismo , Relación Estructura-Actividad , Tubulina (Proteína)/metabolismo , Moduladores de Tubulina/farmacología , Moduladores de Tubulina/uso terapéutico
4.
Sci Rep ; 7(1): 7787, 2017 08 10.
Artículo en Inglés | MEDLINE | ID: mdl-28798407

RESUMEN

The Sanshandao gold deposit contains an estimated Au resource of >1500 tons, however little is known about the history of exhumation, and the magnitude of displacement on the ore-hosting fault. Structural measurement revealed two phases of normal and one phase of sinistral movement on the fault. Despite of intra-sample dispersions, (U-Th)/He ages from two sub-vertical profiles show decreasing trends from the surface down to -3560 m (zircon: 123 Ma to 55 Ma; apatite 103 Ma to 0.3 Ma). Over-dispersion of AHe ages likely reflects the presence of undetected inclusions. According to the age-depth pattern, we infer that the deposit underwent an early phase of rapid cooling in the late Early Cretaceous, which was followed by a short period of thermal stagnation and a revived rapid cooling between 75 Ma and 55 Ma in response to a combined effects of late normal movement and erosion. Since the Eocene, the deposit has experienced a slow monotonic cooling. Exhumation magnitude estimates suggest that the deposit have been denudated > 5.1 km. The two phases of normal displacement along the fault occurred in the late Early Cretaceous and Late Cretaceous to Paleocene, leading to a total offset magnitude of 0.5-2.3 km.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...